Curasight A/S CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented the company, its operations and future plans, via a webcast together with Biostock. See below for more information.
Link to webcast: https://www.youtube.com/watch?v=H9l6tyR1ADE
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.
